arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ABVC BIOPHARMA, INC.

ABVC
$0.97 ▼ -0.02 (-2.44%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

ABVC BIOPHARMA, INC. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $25.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -6.0% ↗
FCF / Share $-0.01 ↗
Trailing P/E —
Price / Book 2.4x
FCF Yield —
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$795.95K
↑ +104.5% —
Net Income Profit after all expenses
$-736.93K
↑ +67.3% —
Operating Margin Operating profit as % of sales
-146.8%
↓ -89.0% —
FCF / Share Free cash flow per share
$-0.01
↑ +73.3% —
Long-Term Debt Long-term obligations
$124.40K
— 0.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Financial Health ↓
44
Cash Quality ↓
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 65 quarters